LTR 151: Sarai Pahla on Managing Supply Chain Disruption Risk in Life Sciences

Summary“Loss of service or device is loss of benefit, which means it naturally increases the risk of our device.”What happens when a highly regulated medical device depends on a tiny, single-sourced component buried deep in a fragile global supply chain?In this Let’s Talk Risk! conversation, host Naveen Agarwal speaks with Dr. Sarai Pahla about why supply chain disruption is no longer just an operations problem. It is a real risk issue for life sciences companies.Sarai brings a rare perspective to this conversation, combining medical training, ERP and IT experience, regulatory affairs, and multilingual medical writing. Together, we explore how supply shocks can disrupt patient access, why alternate sourcing is harder in regulated industries, and how predictive analytics may become essential for future supply chain resilience.Listen to the full 30-minute podcast or jump to a section of interest listed below. Chapters00:00 Introduction05:02 Why modern life sciences supply chains are more vulnerable to disruption08:13 A real example of a single-source component risk in heart valve manufacturing10:27 How supply chain disruption connects directly to patient benefit-risk11:35 Planning ahead: second sources, business continuity, and R&D readiness13:36 Why regulatory-ready suppliers create a strategic advantage16:22 The role of AI and predictive analytics in supply chain risk management23:34 Key takeaways: interdependence, relationships, and future-ready resilienceIf you enjoyed this podcast, consider subscribing to the Let’s Talk Risk! newsletter.Suggested links:LTR: Rethinking Supply Chain Risk: QMSR’s New ExpectationsLTR: It is Time to Focus on Supply Chain Resiliency Not Just Supplier Management.LTR: LTR Risk Coach - AI-Powered Decision Support Tool.Key Takeaways* Supply chain disruption in MedTech is not just a commercial problem. It can directly affect patient access and device benefit.* Single-source components can create outsized risk, especially when they are critical and difficult to replace.* In regulated industries, alternate sourcing is harder because supplier changes often require new evidence, documentation, and regulatory review.* Strong supplier relationships still matter. Trust, transparency, and regulatory understanding are strategic assets.* Forward-looking R&D should include supply chain scenarios, not just technical and regulatory development plans.* Predictive analytics and AI may become important tools for stress-testing supply chains and planning for shocks.* Risk professionals may have an opportunity to expand beyond safety risk into broader supply continuity and resilience strategy.KeywordsSupply chain risk, business continuity, MedTech, life sciences, supplier resilience, regulatory strategy, predictive analytics, AI in supply chain, alternate sourcing, benefit-riskAbout Sarai PahlaSarai Pahla is a medical doctor, regulatory affairs professional, and medical writer based in Düsseldorf, Germany. Her career spans clinical medicine, SAP/ERP security, multilingual medical and regulatory translation, and regulatory writing across medical devices and pharmaceuticals. She currently serves as Principal Medical Writer at Criterion Edge and also leads her own medical and regulatory writing practice. Sarai brings deep experience across EU and global regulatory environments, with particular strength in multilingual source analysis, clinical and regulatory documentation, and emerging applications of AI and data science in regulatory work.Let’s Talk Risk! with Dr. Naveen Agarwal is a bi-weekly live audio event on LinkedIn, where we talk about risk management related topics in a casual, informal way. Join us at 11:00 am EST every other Friday on LinkedIn.DisclaimerInformation and insights presented in this podcast are for educational purposes only, and not as legal advice. Views expressed by all speakers are their own and do not reflect those of their respective organizations.Parts of this article were created using AI-generated content, which was subsequently reviewed, edited, and fact-checked by the author to ensure accuracy and alignment with our standards. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit naveenagarwalphd.substack.com/subscribe